Borrmann type IV gastric cancer should be classified as pT4b disease

Jinyu Huang(Soochow University), Yingying Xu(Wannan Medical College), Yongxi Song(First Hospital of China Medical University), Zhi Zhu(Sun Yat-sen University), Chunyang Lu(Peking University), Zhi‐Feng Miao(Kaohsiung Medical University), Huimian Xu(First Hospital of China Medical University)

Journal of Surgical Research

May 1, 2016

10.1016/j.jss.2016.04.026

Cited by 16

Related Papers

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

|Cancer Communications|2021|657

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

|The Lancet Oncology|2021|436

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

|癌症：英文版|2023|412

Biomarkers of aging

|Science China Life Sciences|2023|362

Microenvironment-Responsive Metal-Phenolic Nanozyme Release Platform with Antibacterial, ROS Scavenging, and Osteogenesis for Periodontitis

|ACS Nano|2023|345